XDR-TB Can Be Treated

More than 60 percent of HIV-negative XDR -TB patients in the study, which was conducted in home and community-based settings in Peru...

Once thought to be incurable, extensively drug-resistant tuberculosis (XDR-TB) can be treated in some patients, if they are not co-infected with HIV and have access to comprehensive care, according to a study published in the August 7 issue of the New England Journal of Medicine (NEJM). More than 60 percent of HIV-negative XDR -TB patients in the study, which was conducted in home and community-based settings in Peru between 1999 and 2002, were successfully treated using a combination of free, individualized drug treatment and additional services, such as surgery, adverse-event management, and nutritional and psychological support.

"It's essential that the world know that XDR-TB is not a death sentence," says lead author Carole Mitnick, a Harvard Medical School instructor in global health and social medicine. The results from Peru, which were even better than some XDR-treatment results in hospitals in Europe, the United States, and Korea, demonstrate that even in settings where there are limited resources, XDR-TB can be cured in many cases on an outpatient basis.

Writing in the same issue of NEJM, Mario C. Raviglione, head of the Stop TB Department of the World Health Organization, praised the study for changing the perception that XDR-TB is untreatable. He cautioned, however, that the high rate of successful treatment in Peru may not be reproducible elsewhere; a strain of XDR-TB reported in Italy, for example, is resistant to all available drugs. And the local capacity for TB treatment in Peru may be exceptional, because it results from cooperation among HMS, the Harvard School of Public Health, Brigham and Women's Hospital, the Massachusetts State Laboratory Institute, and the Lima, Peru-based organizations Socios en Salud, the Hospital Nacional Sergio Bernales, and the Peruvian Ministry of Health.

The question and the challenge now, writes Raviglione, is whether this model of treatment can be scaled up—not just nationally in Peru, but globally.

For more about the global threat of tuberculosis, see "A Plague Reborn."

 

 

 

Related topics

You might also like

Discoveries: Chronic Pain, Cocoa Shortages, and Making Old Lungs Young

Harvard researchers investigate climate’s impact on cocoa crops, innovations in nasal vaccines, and links between pain and skull marrow.

To Promote Healthy Habits in Patients, Start With the Doctors

Why Harvard Medical School is training physicians to think more like coaches

When Government Funding Dropped, Harvard Found Partners

The University is expanding industry ties and investing its own funds to support research, but neither will replace lost federal dollars.

Most popular

How Philosophy at Harvard Saved Itself

As humanities shrink across higher education, one department is flourishing. Is its success a fluke, or a roadmap?

Three Harvard Alumni and a Former Postdoc Named MacArthur Fellows

A labor economist, an organic chemist, a physicist, and a memory researcher were honored with 2026 “genius” grants.

Harvard Stabilizes Finances With Strong Endowment Returns, Philanthropy

Small operating surplus is dwarfed by reduced federal research support and endowment tax liabilities.

Explore More From Current Issue

Black and white portrait of a woman with medium-length hair, smiling softly.

The outgoing executive director and Harvard Business School graduate went from dancing The Nutcracker to growing a ballet company.

Collage of three photos of an athlete in a triathlon: one swimming, one cycling, one running, in sports attire.

The Harvard triathlete and coach says she helps normal people to “do extraordinary things.”

A girl in blue boots stands on a cliff, holding a leash attached to a glowing, digital dog.

Establishing legal responsibility for autonomous agents